NYKD — Nykode Therapeutics ASA Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapNeutral

Annual income statement for Nykode Therapeutics ASA, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	215	34	7.17	12.9	8.68
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	36.7	44.7	60.3	71	57
Operating Profit	178	-10.8	-53.2	-58.1	-48.3
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	181	-11.1	-51	-44.1	-45.5
Provision for Income Taxes
Net Income After Taxes	150	-9.41	-42.7	-35.2	-38.8
Net Income Before Extraordinary Items
Net Income	150	-9.41	-42.7	-35.2	-38.8
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	150	-9.41	-42.7	-35.2	-38.8
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.514	-0.026	-0.142	-0.113	-0.116
Dividends per Share